Development of cancer immune therapy by antibody-recruitment using metabolic labeling

(¹Department of Chemistry, Graduate School of Science, Osaka University, ²PRC, Graduate School of Science, Osaka University) oHersa Milawati,¹ Yoshiyuki Manabe,^{1,2} Kazuya Kabayama,^{1,2} Koichi Fukase,^{1,2}

Keywords: α-gal epitope; anti-Gal antibody; metabolic labelling; antibody recruitment

 α -Gal epitope (Gal- $\alpha(1,3)$ -Gal- $\beta(1,4)$ -GlcNAc) is a trisaccharide antigen which is widely expressed in many animals, but not in humans. Instead, humans produce large amount of antibody which specifically interact with α -gal, termed anti-Gal antibodies. Anti-Gal antibody is the most abundant natural antibodies found in human, consisting of 1-2% of total IgG and 3-8% of total IgM in serum.¹ To develop cancer immune therapy, our group has previously demonstrated the induction of immune responses through antibody recruitment using antibody- α -gal conjugates.²

In this study, we investigated α -Gal presentation on the cancer cell surface by metabolic glycan labeling (MGL) followed by copperfree click chemistry (Fig. 1). MGL has provided facile and powerful method to label cell surface





Fig. 1. Combination of MGL and antibody-recruiting strategy

with chemical tags. Raji cells were first treated with N-azidoacetyl-D-mannosamine (Ac₄ManNAz) to introduce azide group on the cell surface. After confirming the expression of group on the cell azide surface by bioorthogonal copper-free click chemistry using carboxyfluoroscein (FITC)-conjugated DBCO, α -gal was introduced using α -gal-DBCO (α-gal-DBCO). conjugated Furthermore, we investigated complementdependent cytotoxicity (CDC) assay for the agal-presented Raji cells. The α-Gal-presented Raji cells were effectively killed by anti-Gal antibody treatment and the potency was depended on the Ac₄ManNAz and α-Gal-DBCO concentration (Fig. 2).



(1) U. Galili. *Immunol. Cell Biol.* **2005**, *83*, 674-686. (2) J. Sianturi, *et al. Angew. Chem. Int. Ed. Engl.* **2019**, *58*, 4526-4530.